Guided Therapeutics Reports Q3 2024 Results

TL;DR

GTXI Q3: $500M assets, $60.46M liabilities, $54.11M net loss YTD. Series F Preferred Stock issued Oct 10.

AI Summary

Guided Therapeutics Inc. reported its Q3 2024 results, with total assets valued at $500 million and total liabilities at $60.46 million as of September 30, 2024. The company's net loss for the nine months ended September 30, 2024, was $54.11 million. A significant subsequent event involved the issuance of Series F Preferred Stock on October 10, 2024.

Why It Matters

This filing provides insight into Guided Therapeutics' financial health and operational performance for the third quarter of 2024, including its asset base, liabilities, and net loss.

Risk Assessment

Risk Level: medium — The company reported a substantial net loss, indicating potential financial instability.

Key Numbers

• $500.0B — Total Assets (As of September 30, 2024)
• $60.46B — Total Liabilities (As of September 30, 2024)
• $54.11B — Net Loss (YTD) (For the nine months ended September 30, 2024)

Key Players & Entities

• GUIDED THERAPEUTICS INC (company) — Filer
• 500000000 (dollar_amount) — Total Assets as of September 30, 2024
• 60457000 (dollar_amount) — Total Liabilities as of September 30, 2024
• 54105000 (dollar_amount) — Net Loss for the nine months ended September 30, 2024
• 20240930 (date) — Report Period End Date
• 20241114 (date) — Filing Date
• Mr Blumberg (person) — Mentioned in relation to preferred stock
• Shandong Yaohua Medical Instrument (company) — Mentioned in relation to subsequent event

FAQ

Key Financial Figures

• $0.001 — had 61,015,237 shares of Common Stock, $0.001 par value per share, outstanding. PAR
• $153.0 million — an accumulated deficit of approximately $153.0 million. To date, the Company has engaged prima

Filing Documents

• gthp_10q.htm (10-Q) — 1779KB
• gthp_ex101.htm (EX-10.1) — 8KB
• gthp_ex102.htm (EX-10.2) — 11KB
• gthp_ex103.htm (EX-10.3) — 64KB
• gthp_ex104.htm (EX-10.4) — 64KB
• gthp_ex31.htm (EX-31) — 11KB
• gthp_ex32.htm (EX-32) — 5KB
• 0001477932-24-007162.txt ( ) — 7989KB
• gthp-20240930.xsd (EX-101.SCH) — 93KB
• gthp-20240930_lab.xml (EX-101.LAB) — 459KB
• gthp-20240930_cal.xml (EX-101.CAL) — 55KB
• gthp-20240930_pre.xml (EX-101.PRE) — 398KB
• gthp-20240930_def.xml (EX-101.DEF) — 272KB
• gthp_10q_htm.xml (XML) — 1267KB

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION Page Item 1.

Financial Statements

Financial Statements Unaudited Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 3 Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2024 and 2023 5 Unaudited Condensed Consolidated Statements of Stockholders' Deficit for the Three and Nine Months Ended September 30, 2024 and 2023 6 Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023 10 Notes to Unaudited Condensed Consolidated Financial Statements 11 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 39 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 46 Item 4.

Controls and Procedures

Controls and Procedures 46

— OTHER INFORMATION

PART II — OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 47 Item 1A.

Risk Factors

Risk Factors 47 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 47 Item 3. Defaults Upon Senior Securities 47 Item 4. Mine Safety Disclosures 47 Item 5. Other Information 47 Item 6. Exhibits 48

Signatures

Signatures 49 2 Table of Contents GUIDED THERAPEUTICS, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited, in thousands) September 30, December 31, 2024 2023 ASSETS Current Assets: Cash and cash equivalents $ 194 $ 591 Trade receivables, net of allowance for doubtful accounts of nil and $ 2 at September 30, 2024 and December 31, 2023, respectively. 2 7 Inventory, net of reserves of $ 818 at September 30, 2024 and December 31, 2023 636 632 Other current assets 211 163 Total current assets 1,043 1,393 Non-Current Assets: Property and equipment, net 25 32 Operating lease right-of-use assets, net of amortization 164 227 Other assets 17 17 Total non-current assets 206 276 TOTAL ASSETS $ 1,249 $ 1,669 LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities: Accounts payable $ 2,100 $ 1,991 Accounts payable, related parties 32 32 Accrued liabilities 923 1,068 Deferred revenue 748 424 Current portion of lease liability 102 91 Short-term notes payable due to related parties 68 - Current portion of long-term debt, related parties 525 39 Short-term notes payable 228 59 Short-term convertible debt 149 1,105 Short-term convertible debt in default 1,130 - Derivative liability at fair value 20 - Total current liabilities 6,025 4,809 Long-Term Liabilities, Net of Current Portion Long-term lease liability 76 155 Long-term notes payable 53 - Long-term debt, related parties 13 511 Total long-term liabilities 142 666 Total liabilities 6,167 5,475 COMMITMENTS AND CONTINGENCIES (Note 6) 3 Table of Contents STOCKHOLDERS' DEFICIT: Series C convertible preferred stock, $ 0.001 par value; 9.0 shares authorized, 0.3 shares issued and outstanding as of September 30, 2024 and December 31, 2023. Liquidation preference of $ 286 at September 30, 2024 and December 31, 2023. 105 105 Series C1 con

View Full Filing

View this 10-Q filing on SEC EDGAR